When Inappropriate Use of Insulin is Dangerous: The Utility of C-Peptide Assay in the Era of Cardioprotective Antidiabetic Drugs

• DOI: 10.2147/dmso.s321340
• Publication Date: 2021-08-04T12:00:39Z
• Authors: Sara Volpe; Cosimo Tortorella; Vincenzo Solfrizzi; Giuseppina Piazzolla
• Keywords: obesity; diabetes; 610; Specialties of internal medicine; Case Report; metabolic syndrome; 3. Good health; 03 medical and health sciences; hypoglycemia; 0302 clinical medicine; quality of life; RC581-951; diabete; 616; dulaglutide; quality of life.; Targets and Therapy [Diabetes, Metabolic Syndrome and Obesity]

New antidiabetic drugs have simplified treatment regimens in patients with type-2 diabetes (T2D). More importantly, they proven to reduce cardiovascular risk by lowering insulin-resistance, blood pressure and body weight, addition avoiding inappropriate insulin therapy, responsible for hypoglycemic episodes weight gain. In this context, accurate assessment of the metabolic status T2D becomes essential. The C-peptide assay is a simple but often overlooked test that can provide fundamental contribution correct disease classification optimal therapeutic management diabetic patients.We report case 72-year-old patient, treated 26 years after diagnosis type-1 (T1D), resulting inadequate glycemia control severe evolution complications. After an evaluation clinical history, phenotype laboratory data, including determination serum levels, was made not T1D. Considering patient's very high dysmetabolic profile, therapy discontinued more appropriate dulaglutide metformin instituted. These overall modifications yielded remarkable advantages terms glycometabolic reduction, abdominal circumference mass index decrease, as well better quality life, complete resolution dangerous episodes.In era new cardioprotective drugs, we believe importance should be re-evaluated order avoid misdiagnosis improve approach T2D.